BNT327 Optimized Dose

Phase 2Small molecule

BioNTech

BNT327 Optimized Dose is one of 55 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Locally Advanced Breast CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Locally Advanced Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Tykerb

GSK

Preclinical

80 3

Prolia

Amgen

Preclinical

14 4

MS Contin

Merck & Co.

Preclinical

2 5

BNT327 Optimized Dose

BioNTech

Phase 2

2 6

Zolymbus

AbbVie

Preclinical

1 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 9

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Lung Cancer

NCT06449209

Q2 2029

Phase 2Active, not recruiting

Locally Advanced Breast Cancer

NCT06449222

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449209·110 enrolled

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449222·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BNT327 Optimized Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT327 Optimized Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT327 Optimized Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BioNTech

BNT327 Optimized Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2029

Trials by Indication[1]

Lung Cancer1 trial

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News